growth differentiation factor 3
Senast uppdaterad 30 sep 2025
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
The GDF3 gene provides instructions for making a protein that is part of the transforming growth factor beta (TGFβ) superfamily, which is a group of proteins that help control the growth and development of tissues throughout the body. Within the TGFβ superfamily, the GDF3 protein belongs to the bone morphogenetic protein family, which helps regulate the growth and maturation (differentiation) of bone and cartilage. Cartilage is a tough but flexible tissue that makes up much of the skeleton during early development. The proteins in this family help regulate cell growth and differentiation both before and after birth. While the GDF3 protein is known to be involved in bone and cartilage development, its exact role is unclear.
Videoval för GenesVideobibliotek
Normal function
The GDF3 gene provides instructions for making a protein that is part of the transforming growth factor beta (TGFβ) superfamily, which is a group of proteins that help control the growth and development of tissues throughout the body. Within the TGFβ superfamily, the GDF3 protein belongs to the bone morphogenetic protein family, which helps regulate the growth and maturation (differentiation) of bone and cartilage. Cartilage is a tough but flexible tissue that makes up much of the skeleton during early development. The proteins in this family help regulate cell growth and differentiation both before and after birth. While the GDF3 protein is known to be involved in bone and cartilage development, its exact role is unclear.
The GDF3 protein is also involved in the development of the eyes, specifically the specialized light-sensitive tissue that lines the back of the eye called the retina.
Conditions referring to this gene or chromosome
Other names
GDF-3
growth/differentiation factor 3
Related patient information and medicines

Patient information leaflet
Halscancer
(The throat is usually spr... Dr Krishna Vakharia, 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their GP for suspected cancer. To confirm the diagnosis If anything suspicious is seen by the.

Patient information leaflet
Peniscancer
Den exact reason why a cell becomes cancerous is un. It is thought that something damages or alters certain genes in the cell. By looking at certain features of the cells under the ... Grade 1 (low grade) - the cells look reasonably similar to normal cells. The cancer cells are said to be 'well differentiated'. Grade 2 - is a middle grade. Grade 3.

Patient information leaflet
Diabetisk retinopati
New abnormal blood ... This is called proliferative retinopathy. These new vessels are delicate and can bleed easily. There are signs of blood flow becoming restricted but not yet showing new blood vessels growing (see below). Stage 3: proliferative retinopathy Proliferative retinopathy is the advanced diabetic retinopathy that occurs when damaged.

Patient information leaflet
Bröstcancer
Breast cancer is the most common cancer in women. What is breast cancer? | Patient Explainers Breast cancer is the most common cancer in women. Find out more: [/health/breast-cancer-leaflet](https://patient.info/health/breast-cancer-leaflet) Follow Patient: Website: [/](https://patient.info/) Facebook:.

Patient information leaflet
Akromegali
Akromegali is a rare, progressive condition in which you make too much growth hormone. This causes a range of symptoms that develop gradually, often over several years. The most noticeable symptoms are that your hands and feet become larger and features of your face may become more prominent. The cause is usually a small non-cancerous growth.

Patient information leaflet
Högt blodtryck under graviditeten
Developing chronic hypertension in later life. The risks to your baby include: An increased chance of poor growth and a low birth weight. An increased chance of premature birth Premature labour. You may be offered a placental growth factor blood test to help rule out pre-eclampsia between 20 weeks och up till 35 weeks of pregnancy, if you are.
Vidare läsning och referenser
- growth differentiation factor 3; MedlinePlus, National Library of Medicine.
- Frikha R. Klippel-Feil syndrome: a review of the literature. Clin Dysmorphol. 2020 Jan;29(1):35-37. doi: 10.1097/MCD.0000000000000301.
- Jae-Min Park A, Nelson SE, Mesfin A. Klippel-Feil Syndrome: Clinical Presentation and Management. JBJS Rev. 2022 Feb 15;10(2). doi: 10.2106/JBJS.RVW.21.00166.
- Levine AJ, Brivanlou AH. GDF3 at the crossroads of TGF-beta signaling. Cell Cycle. 2006 May;5(10):1069-73. doi: 10.4161/cc.5.10.2771. Epub 2006 May 15.
- Levine AJ, Levine ZJ, Brivanlou AH. GDF3 is a BMP inhibitor that can activate Nodal signaling only at very high doses. Dev Biol. 2009 Jan 1;325(1):43-8. doi: 10.1016/j.ydbio.2008.09.006. Epub 2008 Sep 18.
- Litrenta J, Bi AS, Dryer JW. Klippel-Feil Syndrome: Pathogenesis, Diagnosis, and Management. J Am Acad Orthop Surg. 2021 Nov 15;29(22):951-960. doi: 10.5435/JAAOS-D-21-00190.
- Menger RP, Rayi A, Notarianni C. Klippel Feil Syndrome. 2024 May 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK493157/
- Ye M, Berry-Wynne KM, Asai-Coakwell M, Sundaresan P, Footz T, French CR, Abitbol M, Fleisch VC, Corbett N, Allison WT, Drummond G, Walter MA, Underhill TM, Waskiewicz AJ, Lehmann OJ. Mutation of the bone morphogenetic protein GDF3 causes ocular and skeletal anomalies. Hum Mol Genet. 2010 Jan 15;19(2):287-98. doi: 10.1093/hmg/ddp496. Epub 2009 Oct 28.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
30 sep 2025 | Senaste versionen
1 Sept 2025 | Ursprungligen publicerad
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.

